Oryzon announces First-Patients-in in CLEPSIDRA: a Phase IIa clinical trial with Iadademstat (ORY-1001) in Small Cell Lung Cancer patients
MADRID, SPAIN and CAMBRIDGE MA.
• In Second line patients in combination with Standard-of-Care
• Uses Proprietary Biomarkers as Inclusion Criteria
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today the inclusion of the first two patients in a Phase IIa clinical study with Iadademstat (ORY-1001) in Small Cell Lung Cancer (SCLC) patients.